RecruitingType 2 Diabetes Mellitus

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

Eligible age

18+ yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Sponsor: AstraZeneca

You may qualify if…

✓ Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
✓ T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication
✓ HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
✓ Body mass index (BMI) of ≥ 23 kg/m2 at screening
✓ Stable body weight (self-reported or documented) for 90 days prior to screening

You may not qualify if…

✕ Type 1 diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
✕ Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
✕ Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
✕ Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
✕ History of acute or chronic pancreatitis
✕ Severe congestive heart failure (New York Heart Association IV)
✕ History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2